AIM
ACOR

Alambic Investment Management’s Acorda Therapeutics ACOR Stock Holding History

Alambic Investment Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-130
Closed -$446K – 391
2018
Q2 		$446K Sell
130
-1,307
-91% -$4M 0.12% 226
2018
Q1 		$4.08M Sell
1,437
-194
-12% -$581K 0.57% 37
2017
Q4 		$4.2M Sell
1,631
-349
-18% -$992K 0.51% 53
2017
Q3 		$5.62M Buy
1,980
+167
+9% +$440K 0.61% 30
2017
Q2 		$4.29M Buy
1,813
+758
+72% +$1.5M 0.52% 39
2017
Q1 		$2.66M Buy
1,055
+295
+39% +$849K 0.33% 77
2016
Q4 		$1.72M Buy
760
+407
+115% +$968K 0.3% 104
2016
Q3 		$886K Buy
353
+181
+105% +$540K 0.21% 180
2016
Q2 		$527K Buy
172
+7
+4% +$22.8K 0.13% 267
2016
Q1 		$523K Buy
+165
New +$685K 0.17% 207

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alambic Investment Management's ACOR Position: Q3 2018 in Review

Alambic Investment Management sold out of Acorda Therapeutics (ACOR) in Q3 2018, closing a stake of 130 shares — an estimated $446K sold.

Alambic Investment Management first reported a position in ACOR in Q1 2016 and held it in 10 quarters. The position peaked at $5.62M in Q3 2017. 174 funds tracked by Wall St. Rank hold ACOR as of Q3 2018.

  • Alambic Investment Management reported no remaining Acorda Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Alambic Investment Management sold 130 Acorda Therapeutics shares in Q3 2018, an estimated $446K.
  • Alambic Investment Management first reported a position in Acorda Therapeutics in Q1 2016 and held it in 10 quarters.
  • Alambic Investment Management's Acorda Therapeutics position peaked at $5.62M in Q3 2017.
  • 174 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2018.

Based on Alambic Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.